Perioperative chemotherapy for operable gastro-oesophageal cancer - horizon scanning review
NHSC
Record ID 32005001223
English
Authors' objectives:
This study aims to assess the effectiveness of perioperative chemotherapy for operable gastro-oesophageal cancer.
Authors' recommendations:
Perioperative combination chemotherapy consisting of 3 pre-operative and 3 post-operative cycles of epirubicin, cisplatin and 5-fluorouracil (ECF) has been investigated in a MRC-funded trial for patients with operable gastro-oesophageal cancer suitable for curative resection. 5-FU is being replaced by capecitabine (oral) in a planned study. A randomised controlled trial, published in abstract, of 503 patients demonstrated substantial survival advantage in the use of ECF perioperative chemotherapy, with an increase in survival at five years from 23% to 36%.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Chemotherapy, Adjuvant
- Cisplatin
- Epirubicin
- Fluorouracil
- Esophageal Neoplasms
- Stomach Neoplasms
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.